Citius Pharmaceuticals, Inc. current report, 23 October 2023

Full document

Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary

Business Context and Reporting Period

Date of Report: October 23, 2023
Company: Citius Pharmaceuticals, Inc. ("Citius Pharma")
Event: Entry into a Material Definitive Agreement (Merger Agreement) for a Business Combination with TenX Keane Acquisition ("TenX"), a special purpose acquisition company (SPAC).

Citius Pharma and its wholly-owned subsidiary, Citius Oncology, Inc. ("SpinCo"), have agreed to merge with TenX. Upon closing, TenX will domesticate as a Delaware corporation, merge with SpinCo, and change its name to "Citius Oncology, Inc." ("New Citius Oncology"). The transaction was unanimously approved by the boards of directors of Citius Pharma, SpinCo, and TenX.

Key Financial Metrics and Transaction Structure

Consideration and Exchange Ratio:

  • Base Exchange Ratio: Calculated as 67,500,000 divided by the aggregate number of SpinCo Common Stock shares outstanding immediately prior to the Effective Time.
  • Share Conversion: Each outstanding SpinCo share will convert into New Citius Oncology Shares based on the Base Exchange Ratio.
  • Option Conversion: Outstanding SpinCo options will convert into options for New Citius Oncology Shares with adjusted exercise prices.

Liquidity and Capital Requirements:

  • Net Tangible Assets: TenX must have at least $5,000,001 in net tangible assets at or prior to the Effective Time.
  • Trust Account: New Citius Oncology must have at least $2,000,000 remaining in the liquidated Trust Account Property following shareholder redemptions to reimburse the Sponsor for Extension Promissory Notes.
  • Transaction Expenses: The Sponsor is obligated to pay Estimated Parent Transaction Expenses in excess of $500,000.

Note: This filing does not provide specific revenue, profit, cash flow, or margin figures for Citius Pharma or TenX. It focuses on the terms of the merger agreement.

Material Changes and Transaction Timeline

Expected Closing: First half of 2024, subject to closing conditions.
Outside Date: September 30, 2024 (the deadline by which the Closing must occur or the agreement may be terminated).

Key Conditions to Closing:

  • Approval by TenX shareholders and Citius Pharma (as SpinCo's sole shareholder).
  • Effectiveness of the Registration Statement filed by TenX.
  • Receipt of requisite regulatory approvals (including HSR Act).
  • Completion of TenX's domestication to Delaware.
  • Absence of Material Adverse Effects for both parties.
  • Nasdaq listing requirements met for New Citius Oncology.

Guidance, Risks, and Contingencies

Termination Rights and Fees:

  • Termination Fee: Citius Pharma may terminate the agreement prior to February 29, 2024, to accept a superior Acquisition Proposal, provided it pays a $5,000,000 Termination Fee to TenX.
  • FDA Risk: Either party may terminate if the FDA issues a complete response letter regarding the biologics license application (BLA) for Lymphir (denileukin diftitox).
  • Breach Termination: Either party may terminate for uncured breaches of representations or warranties.

Lock-Up Provisions:
The Sponsor and certain Citius Oncology stockholders are restricted from transferring New Citius Oncology Shares for six months post-closing, unless the share price exceeds $12.00 for 20 trading days within a 30-day period or a cash-out transaction occurs.

Forward-Looking Risks:
The filing highlights significant risks including the potential failure to complete the Business Combination, FDA approval uncertainties for Lymphir, the need for substantial additional funding, and market volatility. The transaction is not guaranteed to close.

Investor Verification Checklist

  • Exchange Ratio Calculation: Verify the final number of SpinCo shares outstanding to determine the precise Base Exchange Ratio and implied valuation.
  • Trust Account Balance: Confirm the amount remaining in TenX's Trust Account after any shareholder redemptions to ensure the $2,000,000 minimum for Sponsor reimbursement is met.
  • Regulatory Status: Monitor the status of the BLA resubmission for Lymphir, as an FDA complete response letter is a specific termination trigger.
  • Shareholder Approval: Track the outcome of the TenX shareholder vote required to approve the Merger Agreement.
  • Financing Needs: Review subsequent filings for details on the "substantial additional funds" required for Citius Oncology's operations post-merger.